MCM2基因和蛋白在乳腺癌组织中的表达及其临床意义

摘要

目的：探讨微型染色体维持蛋白2（ minichromosome maintenance proteins 2，MCM2）基因和蛋白水平在乳腺癌组织中的表达变化及其临床意义。方法应用RT-PCR技术，半定量检测在54例乳腺癌组织、12例乳腺良性疾病组织和10例正常乳腺组织中MCM2 mRNA的表达水平。应用Western-blotting技术检测MCM2蛋白在上述组织中的表达变化。结果正常乳腺组织、良性和恶性乳腺肿瘤组织中MCM2 mRNA和蛋白表达水平比较存在统计学差异（ P＜0．05），且随着肿瘤恶性程度的升高呈逐渐增高趋势。 MCM2 mRNA和蛋白表达量在不同TNM分期和不同病理类型乳腺癌组织间存在统计学差异（P＜0．05），但Ⅰ期与Ⅱ期、Ⅲ期与Ⅳ期间MCM2表达却无统计学差异（P＞0．05）。结论MCM2可以用于判断乳腺癌的恶性程度和病理分级的高低，可能为乳腺癌的未来基因治疗提供一个新的潜在分子靶点和理论依据。%Objective To investigate the expression of minichromosome maintenance protein 2 ( MCM2 ) mRNA and protein in breast cancer and its clinical significance .Methods Reverse transcription polymerase chain reaction (RT-PCR) was used in semi quantitative detection of the expression of MCM 2 mRNA in 54 cases of breast cancer ,12 cases of benign breast tumor,and 10 cases of normal breast tissues .The expression of MCM2 protein in the above tissues was detected by Western-blot-ting.Results The expression of MCM2 mRNA and protein were significantly different among normal breast ,benign breast tumor and breast cancer tissues .The higher degree of malignancy breast cancer showed ,the higher expression of MCM 2 mRNA and pro-tein were (P<0.05).The expression of MCM2 mRNA and protein showed a statistically significant association with TNM staging and histological grade (P<0.05).There was no significant difference in the expression of MCM 2 between stage ⅠandⅡbreast cancer (P>0.05).The similar result was found between stage Ⅲand Ⅳ breast cancer (P>0.05).Conclusion MCM2 may serve as a reliable and useful diagnostic marker for breast cancer and can evaluate the degree of malignancy and differentiation in breast cancer .MCM2 may serve as a new potential biomarker and theoretic basis in the gene therapy for breast cancer .